Cargando…

Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification

Traumatic heterotopic ossification (HO) is the abnormal formation of bone in soft tissues as a consequence of injury. However, the pathological mechanisms leading to traumatic HO remain unknown. Here, we report that aberrant expression of IL‐17 promotes traumatic HO formation by activating β‐catenin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Bing, Yu, Bo, Wang, Wei, Li, Juehong, Yuan, Feng, Zhu, Jing, Fan, Cunyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358870/
https://www.ncbi.nlm.nih.gov/pubmed/34189826
http://dx.doi.org/10.1111/jcmm.16617
_version_ 1783737428929937408
author Tu, Bing
Yu, Bo
Wang, Wei
Li, Juehong
Yuan, Feng
Zhu, Jing
Fan, Cunyi
author_facet Tu, Bing
Yu, Bo
Wang, Wei
Li, Juehong
Yuan, Feng
Zhu, Jing
Fan, Cunyi
author_sort Tu, Bing
collection PubMed
description Traumatic heterotopic ossification (HO) is the abnormal formation of bone in soft tissues as a consequence of injury. However, the pathological mechanisms leading to traumatic HO remain unknown. Here, we report that aberrant expression of IL‐17 promotes traumatic HO formation by activating β‐catenin signalling in mouse model. We found that elevated IL‐17 and β‐catenin levels are correlated with a high degree of HO formation in specimens from patients and HO animals. We also show that IL‐17 initiates and promotes HO progression in mice. Local injection of an IL‐17 neutralizing antibody attenuates ectopic bone formation in a traumatic mouse model. IL‐17 enhances the osteoblastic differentiation of mesenchymal stem cells (MSCs) by activating β‐catenin signalling. Moreover, inhibition of IL‐17R or β‐catenin signalling by neutralizing antibodies or drugs prevents the osteogenic differentiation of isolated MSCs and decreases HO formation in mouse models. Together, our study identifies a novel role for active IL‐17 as the inducer and promoter of ectopic bone formation and suggests that IL‐17 inhibition might be a potential therapeutic target in traumatic HO.
format Online
Article
Text
id pubmed-8358870
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83588702021-08-15 Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification Tu, Bing Yu, Bo Wang, Wei Li, Juehong Yuan, Feng Zhu, Jing Fan, Cunyi J Cell Mol Med Original Articles Traumatic heterotopic ossification (HO) is the abnormal formation of bone in soft tissues as a consequence of injury. However, the pathological mechanisms leading to traumatic HO remain unknown. Here, we report that aberrant expression of IL‐17 promotes traumatic HO formation by activating β‐catenin signalling in mouse model. We found that elevated IL‐17 and β‐catenin levels are correlated with a high degree of HO formation in specimens from patients and HO animals. We also show that IL‐17 initiates and promotes HO progression in mice. Local injection of an IL‐17 neutralizing antibody attenuates ectopic bone formation in a traumatic mouse model. IL‐17 enhances the osteoblastic differentiation of mesenchymal stem cells (MSCs) by activating β‐catenin signalling. Moreover, inhibition of IL‐17R or β‐catenin signalling by neutralizing antibodies or drugs prevents the osteogenic differentiation of isolated MSCs and decreases HO formation in mouse models. Together, our study identifies a novel role for active IL‐17 as the inducer and promoter of ectopic bone formation and suggests that IL‐17 inhibition might be a potential therapeutic target in traumatic HO. John Wiley and Sons Inc. 2021-06-29 2021-08 /pmc/articles/PMC8358870/ /pubmed/34189826 http://dx.doi.org/10.1111/jcmm.16617 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Tu, Bing
Yu, Bo
Wang, Wei
Li, Juehong
Yuan, Feng
Zhu, Jing
Fan, Cunyi
Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification
title Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification
title_full Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification
title_fullStr Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification
title_full_unstemmed Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification
title_short Inhibition of IL‐17 prevents the progression of traumatic heterotopic ossification
title_sort inhibition of il‐17 prevents the progression of traumatic heterotopic ossification
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358870/
https://www.ncbi.nlm.nih.gov/pubmed/34189826
http://dx.doi.org/10.1111/jcmm.16617
work_keys_str_mv AT tubing inhibitionofil17preventstheprogressionoftraumaticheterotopicossification
AT yubo inhibitionofil17preventstheprogressionoftraumaticheterotopicossification
AT wangwei inhibitionofil17preventstheprogressionoftraumaticheterotopicossification
AT lijuehong inhibitionofil17preventstheprogressionoftraumaticheterotopicossification
AT yuanfeng inhibitionofil17preventstheprogressionoftraumaticheterotopicossification
AT zhujing inhibitionofil17preventstheprogressionoftraumaticheterotopicossification
AT fancunyi inhibitionofil17preventstheprogressionoftraumaticheterotopicossification